知Yizhi Daily
← Back to this edition

Business & markets

2026 medical insurance and commercial insurance “dual catalogs” released in Suzhou; medical insurance adds 107 drugs

Edition 2026-11-16 · 08:00 Beijing time

The 2026 High-Quality Development Conference for Innovative Drugs was held in Suzhou, Jiangsu Province, on November 14, where the new version of the national medical insurance drug catalog and the commercial health insurance innovative drug catalog were released. The national medical insurance catalog added 107 drugs, including 51 Class 1 innovative drugs, a record-high number, bringing the total number of drugs in the catalog to 3,331.

According to China News Network, the 2026 High-Quality Development Conference for Innovative Drugs was held in Suzhou on November 14, where the new version of the national medical insurance drug catalog and the commercial health insurance innovative drug catalog were released. This marks the ninth adjustment to the national basic medical insurance drug catalog since the National Healthcare Security Administration was established.

The new national medical insurance catalog adds 107 drugs, including 51 Class 1 innovative drugs, a record high. The newly added drugs cover clinically urgently needed areas such as tumors, rare diseases, chronic diseases and mental illnesses. The 2026 edition contains a total of 3,331 drugs, including 1,935 Western medicines and 1,396 Chinese patent medicines.

The biomedical industry foundation of host city Suzhou drew attention. In 2025, the output value of enterprises above designated size in Suzhou’s biomedical and big health industry cluster exceeded 250 billion yuan. Seven Class 1 innovative drugs and 10 Class III innovative medical devices were approved during the year, and the cumulative number of approved Class 1 innovative drugs reached 21. BioBAY in Suzhou Industrial Park has gathered more than 680 biomedical and big health-related enterprises and nearly 35,000 research and development personnel.

Yu Dechao, founder, chairman and chief executive officer of Innovent Biologics, said 17 of the company’s drugs have been included in medical insurance, benefiting more than 20 million patients. He cited the company’s PD-1 inhibitor Tyvyt, whose annual cost before reimbursement was 36,000 yuan after it entered medical insurance in 2019. Tang Kaiyu, president of MSD China, said two of the company’s products, Xinruilai and Weilirui, were selected this time, and it now has 22 products included in the national medical insurance drug catalog.

Original sources

中新网财经 ↗
Back to this editionOpen interactive reader